BioNTech Navigates a Pivotal Week: Oncology Data at ASCO and FDA Vaccine Guidance in Focus
Published on 05/28/2026 at 12:24 | Redaktion boerse-global.de
The coming days will test BioNTech’s ability to juggle two vastly different strategic fronts. While the company’s oncology pipeline takes centre stage at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago from 29 May to 2 June, a separate regulatory event in Washington on Thursday could shape the near-term trajectory of its shrinking Covid vaccine business.
The FDA’s Vaccines and Related Biological Products Advisory Committee (VRBPAC) is scheduled to convene virtually from 14:30 to 22:30 MEZ. The core question for the panel: should the XFG variant, a descendant of the JN.1 lineage, be designated the preferred strain for an updated monovalent vaccine for the 2026-2027 season? The FDA’s briefing documents also flag BA.3.2 as an alternative from a different sublineage. A recommendation in favour of XFG would allow Pfizer-BioNTech and other licensed manufacturers to align production timelines for the autumn booster campaign. Pfizer-BioNTech has been given a dedicated 20-minute slot, from 17:20 to 17:40, to present current Comirnaty data, alongside presentations from Moderna, Sanofi, the CDC and the WHO.
That regulatory checkpoint matters because the Covid vaccine franchise is no longer the growth engine it once was. First-quarter revenue slid to €118.1 million from €182.8 million a year earlier, underscoring the secular decline in demand. A new study published in Nature Communications reaffirms BNT162b2’s efficacy across clinical settings, including infection prevention and transmission reduction, but such validation no longer moves the stock. The market’s gaze has shifted firmly to the oncology pipeline.
Should investors sell immediately? Or is it worth buying BioNTech?
At ASCO, the spotlight will fall on pumitamig, a bispecific immunomodulator targeting PD-L1 and VEGF-A. BioNTech has already launched five registrational trials this year across triple-negative breast cancer, gastric cancer and non-small cell lung cancer. Encouraging interim results from the phase 2 ROSETTA Lung-02 study, where pumitamig combined with chemotherapy showed antitumour activity, have fed into an ongoing phase 3 trial comparing the candidate head-to-head against pembrolizumab. The company expects to initiate six more phase 3 studies by year-end, potentially bringing its late-stage oncology programme to 15 registrational trials. That expansion broadens the shot at success but also keeps financial pressure high.
Indeed, research and development costs surged to €557.0 million in the first quarter, reflecting accelerated clinical execution across more than 25 ongoing phase 2 and phase 3 studies. Yet the balance sheet provides ample runway. BioNTech ended March with roughly $19.6 billion in cash, equivalents and marketable securities, while a $1.0 billion share buyback programme runs over the next twelve months.
The stock itself reflects the uneasy transition. The US-listed shares closed Wednesday at about $93, a 0.8% gain on the day, but remain roughly 3% lower year-to-date. The 52-week high near $102 from June 2025 is about 21% above current levels. On the Frankfurt exchange, the shares trade at €79.65, down 8.61% over the past month despite a modest recent recovery. Technically, the stock sits just below its 50-day moving average but 7.61% under the 200-day average – a sign of short-term stabilisation rather than a clear uptrend.
For BioNTech, the quality of the clinical signals from pumitamig and the other oncology programmes at ASCO will carry more weight than the sheer number of presentations. A convincing readout would lend credibility to the strategic pivot from vaccine specialist to cancer drug developer. Meanwhile, the FDA panel’s verdict on XFG will determine whether the autumn vaccine campaign can stick to schedule – a less glamorous but equally vital piece of the puzzle. Both events, taken together, will shape investor perception of BioNTech’s ability to manage its dual identity in the months ahead.
Ad
BioNTech Stock: New Analysis - 28 May
Fresh BioNTech information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
